{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:28:13Z","timestamp":1791300493714,"version":"4.1.0"},"reference-count":38,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,12,28]],"date-time":"2015-12-28T00:00:00Z","timestamp":1451260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>This study aimed to describe the real\u2010life incidence of bleeding, arterial thrombotic events and death during vitamin K antagonist (VKA) treatment in atrial fibrillation (AF).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a cohort study in Echantillon G\u00e9n\u00e9raliste de B\u00e9n\u00e9ficiaires, the 1\/97 sample of the <jats:styled-content style=\"fixed-case\">French<\/jats:styled-content> national healthcare claims and hospitalization database, of new VKA users with definite or probable AF and no other indication, and of patients without AF, from 2007 to 2011. Prespecified outcomes were all\u2010cause death, hospitalization for bleeding, arterial thrombotic event (ATE), or acute coronary syndrome (ACS) or any of the above (composite outcome).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 8894 new VKA users, 3345 had probable or certain AF, 51.7% were male, mean age was 75.1\u00a0years, 87.1% had a CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>\u2010VASc score\u00a0\u2265\u00a02 and 11.6% a HAS\u2010BLED score\u00a0&gt;\u00a03. Among AF patients, during VKA exposure the incidence rate of bleeding was 2.8 [95% confidence interval (CI) 2.2, 3.4] per 100 patient\u2010years, including 0.6 (95% CI 0.3, 0.8) cerebral, 1.0 (95% CI 0.7, 1.3) digestive and 1.4 (95% CI 1.0, 1.7) other bleeds. There were 1.6 (95% CI 1.2, 2.0) ACS, 1.5 (95% CI 1.1, 1.8) ATE and 3.8 (95% CI 3.2, 4.4) deaths per 100 patient\u2010years. The incidence rate of the composite outcome was 9.1 per 100 patient\u2010years (95% CI 8.2, 10.0). When patients stopped VKA, bleeding decreased (RR 0.67, 95% CI 0.43, 1.04)), but death or thrombosis increased (RR 3.06, 95% CI 2.46, 3.81 and 1.75, 95% CI 1.14, 2.70, respectively). During VKA exposure non\u2010AF patients had similar rates of bleeding, but fewer deaths, ACS and ischaemic events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Real\u2010life rates for bleeding, arterial thrombotic events, ACS and deaths in AF patients treated with VKA were similar to those observed in clinical trials.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.12807","type":"journal-article","created":{"date-parts":[[2015,10,23]],"date-time":"2015-10-23T05:05:49Z","timestamp":1445576749000},"page":"569-578","source":"Crossref","is-referenced-by-count":28,"title":["A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC"],"prefix":"10.1111","volume":"81","author":[{"given":"Patrick","family":"Blin","sequence":"first","affiliation":[{"name":"Bordeaux Pharmacoepi, Inserm CIC1401  Bordeaux"},{"name":"Adera  Bordeaux"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dureau\u2010Pournin","sequence":"additional","affiliation":[{"name":"Bordeaux Pharmacoepi, Inserm CIC1401  Bordeaux"},{"name":"Adera  Bordeaux"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regis","family":"Lassalle","sequence":"additional","affiliation":[{"name":"Bordeaux Pharmacoepi, Inserm CIC1401  Bordeaux"},{"name":"Adera  Bordeaux"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelilah","family":"Abouelfath","sequence":"additional","affiliation":[{"name":"Bordeaux Pharmacoepi, Inserm CIC1401  Bordeaux"},{"name":"Adera  Bordeaux"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Droz\u2010Perroteau","sequence":"additional","affiliation":[{"name":"Bordeaux Pharmacoepi, Inserm CIC1401  Bordeaux"},{"name":"Adera  Bordeaux"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Moore","sequence":"additional","affiliation":[{"name":"Bordeaux Pharmacoepi, Inserm CIC1401  Bordeaux"},{"name":"University of Bordeaux  F33076 Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,12,28]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7241.1036"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12266"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.001139"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.012061"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.5398"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62343-0"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH05-03-0166"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000186"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(89)80689-8"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.respe.2010.04.005"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2014.11.009"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12592"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2429-5"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-07-0552"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.06.003"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.2012.01023.x"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.002332"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.6265"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1302834"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.19.9.2269"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04095.x"},{"key":"e_1_2_10_26_1","first-page":"203","article-title":"Anticoagulant treatment with fluindione. Relation between the decrease of vitamin K\u2010dependent factors and blood fluindione","volume":"41","author":"Roncato M","year":"1986","journal-title":"Therapie"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.271"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eut001"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.8.853"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2012.04.005"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-10-201111150-00004"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-0608"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2012.4261"},{"key":"e_1_2_10_35_1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/jama.2014.61","article-title":"Resuming warfarin after GI bleeding leads to better outcomes","volume":"311","author":"Slomski A","year":"2014","journal-title":"JAMA"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1857"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2317"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.015710"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2014.01.030"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.12807","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.12807","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.12807","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.12807","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T14:37:57Z","timestamp":1694615877000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.12807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,28]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1111\/bcp.12807"],"URL":"https:\/\/doi.org\/10.1111\/bcp.12807","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,28]]}}}